Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amantadine + pregabalin
- Development stage
- Unknown
- Lead developer
- Supernus Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amantadine + pregabalin is a combination of two small molecule drugs used together, primarily investigated for the management of chronic and neuropathic pain. Amantadine is an antiviral and antiparkinsonian agent that also exhibits analgesic properties, likely through increasing dopamine release and antagonism of N-methyl-D-aspartate (NMDA) receptors. Pregabalin is an anticonvulsant and analgesic that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing neurotransmitter release and neuronal excitability. The combination aims to target multiple pain pathways—amantadine modulating dopaminergic transmission and NMDA receptor activity, while pregabalin inhibits excitatory neurotransmission via calcium channel blockade—to provide enhanced pain relief in conditions such as post-surgical pain or chronic neuropathic states[2][4][6][8].
- Other names
- pregabalin and amantadine combination
02
Targets
α2δ (Voltage-gated calcium channel alpha-2-delta subunit)NMDAR (Glutamate receptor ionotropic, NMDA)DAT (Dopamine plasma membrane transport protein)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on amantadine + pregabalin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amantadine + pregabalin.